IDEAYA Biosciences (IDYA) Preferred Stock Liabilities (2018 - 2019)
IDEAYA Biosciences' (IDYA) quarterly Preferred Stock Liabilities came in at $138.4 million in Q1 2019, up 2.83% year-on-year from $134.6 million in Q1 2018, and little changed quarter-over-quarter from $138.4 million in Q4 2018.
IDEAYA Biosciences (IDYA) Preferred Stock Liabilities (2018 - 2019) Analysis & Trends
IDEAYA Biosciences has disclosed Preferred Stock Liabilities across 2 years of filings, most recently posting $138.4 million for Q1 2019.
- Preferred Stock Liabilities for Q1 2019 came in at $138.4 million, up 2.83% year-over-year; the trailing twelve-month figure through Mar 2019 was $138.4 million (up 2.83% YoY), and the FY2018 annual result was $138.4 million, up 430.56% from the prior year.
- Preferred Stock Liabilities came in at $138.4 million for Q1 2019 at IDEAYA Biosciences, roughly flat from $138.4 million in the prior quarter.
- In the past five years, Preferred Stock Liabilities ranged from a high of $138.4 million in Q3 2018 to a low of $134.6 million in Q2 2018.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | - |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | IDEAYA Biosciences | 2.78 Bn | 2.10 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2019 | 138.39 Mn |
| Dec 31, 2018 | 138.39 Mn |
| Sep 30, 2018 | 138.39 Mn |
| Jun 30, 2018 | 134.58 Mn |
| Mar 31, 2018 | 134.59 Mn |